May 22 (Reuters) - Gilead Sciences said on Friday that its experimental drug for a rare and deadly liver infection that had ...
Food and Drug Administration said on Friday it approved Gilead Sciences' drug for a rare and deadly liver infection that ...
Pharmaceutical Technology on MSN
Gilead Sciences completes Tubulis acquisition for $5bn
Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.
Gilead Sciences received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending the marketing authorization of its Trodelvy drug to ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company ...
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs ...
Gilead Sciences received accelerated approval for a chronic hepatitis delta virus treatment from the Food and Drug Administration. The FDA said the Hepcludex treatment, known also as bulevirtide-gmod, ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending ...
Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea | ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Ed’s stories explore prescription drug ...
Moderna (NASDAQ:MRNA | MRNA Price Prediction) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results